Stocks in Play - 24th February 2026

Today in Focus: VIR, PVLA, Delayed Reactions

Sources & Services I Use in my Trading:

• Finviz - Scanning, Short Interest, Float, Fundamentals

• Benzinga Pro - News + Squawk

• Tradingview - Charting & Scanning

• BiopharmaIQ - FDA Calendars & Upcoming Biotech Catalysts

• Koyfin - Fundamental Data

• Tradersync - Trade Journal

Situational Awareness

Market Condition: Below all major Moving Averages. Very narrow trading range. Expansion looming.

Commentary: Very tight trading range on indices. Still seeing mixed progress in positions. Less is more. Picks today are Biotech which should be independent of the market. Some nice delayed reactions also in VRT and PLBY.

Upcoming Earnings:
After Hours: CAVA, TMDX, FSLR, CYTK, HYLN
Before Open: HUT, PLAB, YOU, LFST

Trade Updates:

Current Positions: FSLY, GLW, STM, INNV, CGNX, NKTR, TALK, RXT, ROIV

In Play

VIR: Positive Phase 1 Update. Earnings

Key Metrics: Industry Group: Biotechnology, Market Cap: 1.03B, Float: 94.68M, Short Interest: 12.92%, Days to Cover: 6.65, Sales Y/Y TTM: -78.55%, EPS Y/Y TTM: 7.74%, Earnings: Feb 23 AMC, Exchange: NASDAQ

Catalyst: Vir Biotechnology released updated Phase 1 dose-escalation data for VIR-5500, a PSMA-targeting PRO-XTEN® dual-masked T-cell engager (TCE) in metastatic castration-resistant prostate cancer (mCRPC). Paired with a global strategic collaboration with Astellas for VIR-5500, announced concurrently with Q4 2025 earnings.

I’m seeing positive sentiment around it on my Biotech Social checks. Sitting at $10 level Pre Market which should act as a nice Pivot to trade against.

PVLA:  Positive Phase 3 Data.

Key Metrics: Industry Group: Biotechnology, Market Cap: 1.35B, Float: 8.03M, Short Interest: 17.06%, Days to Cover: 4.95, Sales Y/Y TTM: -, EPS Y/Y TTM: 54.84%, Earnings: Nov 11 BMO, Exchange: NASDAQ

Catalyst: Palvella Therapeutics reported positive topline Phase 3 results for QTORIN rapamycin (3.9% rapamycin anhydrous gel) in microcystic lymphatic malformations (microcystic LMs) — a rare, congenital, progressive vascular disease with zero FDA-approved treatments. showed a mean improvement of +2.13 points (p<0.001). All pre-specified secondary endpoints also achieved p<0.001. 86% of completers were "Much" or "Very Much Improved. Clean Safety. Ticks all the boxes for me. Has already had a significant leg up but on a larger time frame the stock is still quite depressed.

Delayed Reaction/Continuation Watchlist:

Monitoring:

• PLBY

• VRT

Delayed Reaction Watchlist (TradingView Link)

Like what you're reading? Support this work via ☕ Ko-Fi.

_{Note: This is my methodology for identifying stocks in play. There are many valid approaches to trading catalysts—find the setups, timeframes, and risk parameters that align with your strategy.}